2008, the Company has not included any US product sales revenue for
this assay in its guidance, based on the time needed to commercialize
the new indication. Non-product revenues in 2008 are expected to
benefit from an approximately $16 million final payment associated
with the successful settlement of Gen-Probe's patent infringement
claims against Bayer HealthCare (now Siemens Healthcare Diagnostics),
and from a $10 million milestone the Company expects to earn from
Novartis if and when the PROCLEIX ULTRIO assay is fully approved on
the TIGRIS system in the United States.
-- Product gross margins approximating 68% to 70% of product sales. This
improvement over 2007 is expected to result primarily from continued
conversion of PACE customers to the APTIMA Combo 2 assay, from
commercial pricing of the PROCLEIX WNV assay on the TIGRIS system, and
from the leverage inherent in rising manufacturing volumes. These
benefits are expected to be partially offset by continued growth of
the PROCLEIX ULTRIO assay in developing markets, where pricing is less
-- R&D expenses approximating 23% to 24% of total revenues, down slightly
from 2007 as a percentage of revenues. The Company's highest priority
R&D projects for 2008 include the post-marketing HBV yield studies for
the PROCLEIX ULTRIO assay in the United States, development of the
APTIMA human papillomavirus assay, and development of the Panther
instrument platform for low- and mid-volume laboratory customers.
-- Marketing and sales expenses approximating 9% to 10% of total
revenues, similar to 2007 as a percentage of revenues.
-- G&A expenses approximating 11% of total revenues, down slightly
from 2007 as a percentage of revenues.
-- EPS of
|SOURCE Gen-Probe Incorporated|
Copyright©2008 PR Newswire.
All rights reserved